Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
复制标题
DOI：
10.1038/sj.bjc.6690776
复制
发表时间：
1999-11
影响因子：
8.8
通讯作者：
Kainz, C
中科院分区：
文献类型：
--
作者：
Hefler, L;Tempfer, C;Heinze, G;Mayerhofer, K;Breitenecker, G;Leodolter, S;Reinthaller, A;Kainz, C
趋化因子单核细胞趋化蛋白（MCP）-1是各种上皮来源的实体瘤中单核细胞浸润的重要介质。本研究的目的是评估MCP-1在卵巢癌自然史中的作用，并确定其作为无病生存期和总生存期的分化标志物和预后标志物的价值。回顾性研究包括86例卵巢癌患者，48例原发性卵巢癌和38例复发性卵巢癌，67例良性卵巢囊肿和42例健康女性。原发性卵巢癌、复发性卵巢癌、良性卵巢囊肿患者和健康女性的血清中位水平为535.6（范围129.6-1200）pg ml-1，427.3（范围193.4-1101）pg ml-1、371.2（范围222-986.8）pg ml-1和318.7（范围241.3-681.4）pg ml-1（Mann-Whitney U检验，P < 0.001）。单变量logistic回归模型显示MCP-1血清水平分别对原发性卵巢癌与良性囊肿和与健康女性相比的几率有显著影响（单变量logistic回归，分别为P < 0.001和P < 0.001）。在同时考虑MCP-1和CA 125血清水平的多变量逻辑回归模型中，MCP-1和CA 125均显示出原发性卵巢癌与良性囊肿的几率具有统计学显著性（多变量逻辑回归，分别为P = 0.05和P < 0.001）。在卵巢癌患者中，MCP-1血清水平与组织学分级（Mann-Whitney U检验，P = 0.02）和诊断时的年龄（Mann-Whitney U检验，P = 0.03）具有统计学显著相关性。治疗前MCP-1血清水平升高与无病生存期和总生存期无关（对数秩检验，分别为P = 0.2和P = 0.7）。总之，这些数据表明MCP-1可能在卵巢癌的自然史中发挥功能性作用，并可能作为良性卵巢囊肿和卵巢癌之间的分化标志物，为已建立的肿瘤标志物CA 125提供额外的信息。© 1999癌症研究运动
The chemokine monocyte chemoattractant protein (MCP)-1 is an important mediator of monocyte infiltration in various solid tumours of epithelial origin. The aim of the present study was to evaluate the role of MCP-1 in the natural history of ovarian cancer and to determine its value as differentiation marker and prognostic marker regarding disease free and overall survival. This retrospective study comprises 86 patients with ovarian cancer, 48 with primary ovarian cancer and 38 with recurrent ovarian cancer, 67 patients with benign ovarian cysts and 42 healthy women. Median serum levels in patients with primary ovarian cancer, recurrent ovarian cancer, benign ovarian cysts and in healthy women were 535.6 (range 129.6–1200) pg ml–1, 427.3 (range 193.4–1101) pg ml–1, 371.2 (range 222–986.8) pg ml–1 and 318.7 (range 241.3–681.4) pg ml–1 respectively (Mann–Whitney U-test, P < 0.001). Univariate logistic regression models revealed a significant influence of MCP-1 serum levels on the odds of presenting with primary ovarian cancer versus benign cysts and versus healthy women respectively (univariate logistic regression, P < 0.001 and P < 0.001 respectively). In a multivariate logistic regression model considering MCP-1 and CA 125 serum levels simultaneously, both MCP-1 and CA 125 revealed statistical significance on the odds of presenting with primary ovarian cancer versus benign cysts (multivariate logistic regression, P = 0.05 and P < 0.001 respectively). In ovarian cancer patients, MCP-1 serum levels showed a statistically significant correlation with histological grade (Mann–Whitney U-test, P = 0.02) and age at the time of diagnosis (Mann–Whitney U-test, P = 0.03). Elevated MCP-1 serum levels prior to therapy were not associated with disease-free and overall survival (log-rank test, P = 0.2 and P = 0.7 respectively). In summary these data indicate that MCP-1 might play a functional role in the natural history of ovarian cancer and might serve as differentiation marker between benign ovarian cysts and ovarian cancer, providing additional information to the established tumour marker CA 125. © 1999 Cancer Research Campaign
登录
查看更多内容
影响因子：
8.8
作者：
HASKILL, S;BECKER, S;WALTON, L
通讯作者：
WALTON, L
DOI：
10.1093/jnci/85.22.1836
发表时间：
1993-11-17
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
KURATSU, J;YOSHIZATO, K;USHIO, Y
通讯作者：
USHIO, Y
影响因子：
6.4
作者：
DESBAILLETS, I;TADA, M;VAN MEIR, EG
通讯作者：
VAN MEIR, EG
影响因子：
5.5
作者：
Grimm, MC;Elsbury, SKO;Doe, WF
通讯作者：
Doe, WF
影响因子：
6.4
作者：
MELANI, C;PUPA, SM;COLOMBO, MP
通讯作者：
COLOMBO, MP